DAE HWA PHARM CO., LTD
067080 | KO
Overview
Corporate Details
- ISIN(s):
- KR7067080002
- LEI:
- Country:
- South Korea
- Address:
- 강원도 횡성군 횡성읍 한우로 495, 횡성군
- Website:
- http://www.dhpharm.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 34.5 KB | ||
| 2025-09-19 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 31.8 KB | ||
| 2025-09-18 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.8 KB | ||
| 2025-08-20 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 158.8 KB | ||
| 2025-08-11 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.7 MB | ||
| 2025-08-06 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정 (분기배당)
|
Korean | 8.3 KB | ||
| 2025-08-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-07-22 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 158.8 KB | ||
| 2025-06-12 00:00 |
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
|
Korean | 5.4 KB | ||
| 2025-06-12 00:00 |
Related Party Transaction
[기재정정]타인에대한채무보증결정
|
Korean | 24.3 KB | ||
| 2025-06-12 00:00 |
Capital/Financing Update
[기재정정]타인에대한담보제공결정
|
Korean | 25.9 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.4 MB | ||
| 2025-04-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (리포락셀액(파클리탁셀)의 품목허가사항 변경신청 (유방암 신규 적응증 추가를 위한 식품의약품안전…
|
Korean | 16.5 KB | ||
| 2025-04-23 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-04-23 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB |
Automate Your Workflow. Get a real-time feed of all DAE HWA PHARM CO., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for DAE HWA PHARM CO., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAE HWA PHARM CO., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing targeted cancer therapies with a platform that delivers drugs directly to tumors.
United Kingdom
AVCT
United Kingdom
AVCT
Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.
United States of America
AVDL
United States of America
AVDL
Delivers clinical lab services & develops diagnostics, CAR-T therapies, and exosome technology.
United States of America
ALBT
United States of America
ALBT
Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.
United States of America
RNA
United States of America
RNA
Develops surgical solutions, including nerve allografts, for peripheral nerve repair and regeneration.
United States of America
AXGN
United States of America
AXGN
Biopharma company developing novel therapies for central nervous system (CNS) conditions.
United States of America
AXSM
United States of America
AXSM
Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.
United States of America
AYTU
United States of America
AYTU
Developing engineered proteins and live biotherapeutics for rare skin diseases.
United States of America
AZTR
United States of America
AZTR
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Switzerland
BANB
Develops T cell immunotherapies for autoimmune and chronic infectious diseases.
United States of America
BRNS
United States of America
BRNS